Prevalence and severity of fatigue in castration resistant prostate cancer in Spain: VITAL study

Abstract

Background: Fatigue is the most common and distressing symptom of which castration resistant prostate cancer (CRPC) patients complain. The little evidence of fatigue prevalence, intensity and interference with daily activities in advanced prostate cancer that exists is mainly restricted to post-docetaxel setting with Abiraterone Acetate (AA). The VITAL study examines the prevalence and intensity of cancer-related fatigue (CRF) in CRPC. Method(s): cross-sectional study of CRPC patients including chemo-naive metastatic (mCRPC) or high risk M0CRPC (PSADT < 0.05). Mean FACT-P/G total score worsen once fatigue intensity increases (BFI item 3) (p < 0.001, table1). Focusing in mCRPC chemo-naive we found differences in fatigue and QoL according to treatment. Patients receiving Abiraterone (AA) showed better FACT-P total score (Mean [SD]; AA: 119.9 [18.9], others: 103.3[23.1] p = 0.022) and less fatigue interference (BFI item 4 Mean [SD]; AA: 2.3 [2.3], others: 3.2[2.8] p = 0,045). Conclusion(s): Our data show a high prevalence and intensity of fatigue and impact in QoL in chemo-naive CRPC patients. The study highlights the relevance of fatigue awareness and its management in CRPC patients. (Table presented).